Predictors of optimal disease control in atopic dermatitis with abrocitinib: a real-world study.

OBJECTIVES

Abrocitinib is approved for moderate-to-severe atopic dermatitis (AD); however, real-world data evaluating its efficacy in AD control using multidimensional-treatment-targets like optimal-disease-control (ODC) and moderate-disease-control (MDC) remain limited. This study aimed to assess the proportion of patients with moderate-to-severe AD achieving ODC and MDC during abrocitinib-treatment and to explore associated factors.

MATERIALS AND

METHODS

Retrospective multicentric study including patients with moderate-to-severe AD receiving abrocitinib across five hospitals. Disease severity was assessed using clinician-reported-outcomes (EASI, SCORAD, IGA, BSA) and patient-reported-outcomes (peak-pruritus and sleep-disturbance NRS) at baseline and follow-ups. ODC and MDC were defined according to consensus-based criteria, integrating clinician- and patient-reported outcomes.

RESULTS

Fifty-four patients were included (35.1 years; 68.5% men; baseline EASI 25.7 and peak-pruritus NRS 7.5). At final visit (variable follow-up across patients; mean 20.9 weeks), EASI and peak-pruritus NRS decreased to 8.7 and 3.3, respectively. ODC was achieved by 43.8% of patients and MDC by 59.4%. ODC was associated with lower baseline BSA and SCORAD, lower prevalence of allergic conjunctivitis, fewer prior systemic treatments, and less frequent facial involvement.

CONCLUSIONS

In real-world practice, a substantial proportion of patients treated with abrocitinib achieved ODC and MDC. Lower baseline severity and fewer prior systemic therapies were associated with ODC.